Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 21.42% is 16% above its 5-year average of 18.50%, near the high end of its 5-year range (-24.84%–25.75%).
6.31% above its 12-month average of 20.15%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 24.34%.
EBITDA MARGIN
21.42%
EBITDA MARGIN AVG TTM
20.15%
EBITDA MARGIN AVG 3Y
22.33%
EBITDA MARGIN AVG 5Y
18.50%
EBITDA MARGIN AVG 10Y
19.46%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.31%
CURRENT VS 3Y AVG
-4.06%
CURRENT VS 5Y AVG
+15.76%
CURRENT VS 10Y AVG
+10.05%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Amneal Pharmaceuticals, Inc.
Market Cap
$6.45B
EBITDA Margin
21.42%
TTM Avg
20.15%
3Y Avg
22.33%
5Y Avg
18.50%
Market Cap
$6.53B
EBITDA Margin
24.71%
TTM Avg
29.36%
3Y Avg
25.12%
5Y Avg
17.03%
Market Cap
$6.62B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$6.67B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
Market Cap
$6.05B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$5.95B
EBITDA Margin
30.20%
TTM Avg
18.88%
3Y Avg
24.58%
5Y Avg
33.74%
Market Cap
$5.84B
EBITDA Margin
-139.44%
TTM Avg
-176.89%
3Y Avg
-12100.88%
5Y Avg
-12100.88%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.45B | 21.42% | 20.15% | 22.33% | 18.50% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 24.71% | 29.36% | 25.12% | 17.03% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.62B | 6.82% | 6.08% | -0.44% | -8.67% |
| Immunovant, Inc. (IMVT)vs › | $6.66B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.67B | 15.93% | 16.80% | 17.55% | 18.41% |
| GRAIL Inc. (GRAL)vs › | $6.05B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 30.20% | 18.88% | 24.58% | 33.74% |
| Alkermes plc (ALKS)vs › | $6.99B | 19.05% | 23.95% | 20.94% | 15.97% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.84B | -139.44% | -176.89% | -12100.88% | -12100.88% |
| CG Oncology Inc. (CGON)vs › | $5.76B | -4686.36% | -7375.40% | -15092.23% | -12098.10% |
Gross Margin
39.3%
EBITDA Margin
21.4%
Operating Margin
12.9%
Net Margin
5.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 24.34% |
| 2026-03-31 | 25.75% |
| 2025-12-31 | 20.11% |
| 2025-09-30 | 6.88% |
| 2025-06-30 | 23.67% |
| 2025-03-31 | 23.08% |
| 2024-12-31 | 19.43% |
| 2024-09-30 | 21.04% |
| 2024-06-30 | 21.52% |
| 2024-03-31 | 6.79% |
| 2023-12-31 | 11.53% |
| 2023-09-30 | 21.43% |
| 2023-06-30 | 22.90% |
| 2023-03-31 | 16.61% |
| 2022-12-31 | 15.92% |
| 2022-09-30 | 19.42% |
| 2022-06-30 | -24.84% |
| 2022-03-31 | 16.30% |
| 2021-12-31 | 13.48% |
| 2021-09-30 | 16.78% |
| 2021-06-30 | 23.10% |
| 2021-03-31 | 20.57% |
| 2020-12-31 | 15.70% |
| 2020-09-30 | 11.90% |
| 2020-06-30 | 14.81% |
| 2020-03-31 | 23.24% |
| 2019-12-31 | 7.84% |
| 2019-09-30 | -15.57% |
| 2019-06-30 | 7.86% |
| 2019-03-31 | -10.20% |
| 2018-12-31 | 14.22% |
| 2018-09-30 | 24.67% |
| 2018-06-30 | -35.99% |
| 2018-03-31 | 28.45% |
| 2017-12-31 | 31.31% |
| 2017-09-30 | 35.61% |
| 2017-06-30 | 17.17% |
| 2017-03-31 | 23.63% |
| 2016-12-31 | 34.17% |
